ATP Barcelona 2017

1. MRI for targeting: prostate

• Prostate cancer treatment  Boosting dominant intraprostatic lesions (DILs) in the context of stereotactic ablative radiation therapy (SABR)  T2-weighted, dynamic contrast-enhanced and diffusion- weighted magnetic resonance imaging  Prostate planning target volume (PTV) prescription: 42.7 Gy in 7 fractions (6.1 Gy/fr)  Median PTV DIL prescription: 125% (range: 110%-140%)

LJ Murray et al. Prostate Stereotactic Ablative Radiation Therapy Using Volumetric Modulated Arc Therapy to Dominant Intraprostatic Lesions. Int J Radiation Oncol Biol Phys, Vol. 89, No. 2, pp. 406e415, 2014